Multimedia

Povorcitinib improved HiSCR50 responses in moderate-to-severe hidradenitis suppurativa, with higher dosing potentially benefiting patients with more severe disease and a generally favorable safety profile through 54 weeks.

Individualized management of moderate-to-severe atopic dermatitis should consider overall disease burden, patient-specific factors and preferences, and clear treatment expectations to guide systemic therapy selection and support adherence.

Raj Chovatiya, MD, PhD, emphasizes individualized biologic selection, shared decision-making, and adequate treatment optimization before switching therapies in patients with moderate-to-severe atopic dermatitis.

Dr Jason Bloom discusses the evolution of facial rejuvenation from line-filling to comprehensive facial balancing through volumization and biostimulation.

Dr Doris Day discusses why facial fillers continue to grow in popularity by shifting beyond simple volumization toward holistic facial balancing and longevity-focused rejuvenation.

Dr Helen He discusses how cellular senescence and inflammaging work together to accelerate intrinsic and extrinsic skin aging.